Regulus Capital Stock from 2010 to 2024

RGLS Stock

USD 1.61 0.03 1.83%

Regulus Therapeutics Capital Stock yearly trend continues to be comparatively stable with very little volatility. Capital Stock will likely drop to about 23.8 K in 2024. Capital Stock is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. View All Fundamentals

Capital Stock

First Reported

2010-12-31

Previous Quarter

25 K

Current Value

23.8 K

Quarterly Volatility

37.9 K

Credit Downgrade

Yuan Drop

Covid

Check Regulus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regulus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 215.7 K, Interest Expense of 1.1 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 4.03, Dividend Yield of 0.0 or PTB Ratio of 1.75. Regulus financial statements analysis is a perfect complement when working with Regulus Therapeutics Valuation or Volatility modules.

Check out the analysis of Regulus Therapeutics Correlation against competitors.

For more information on how to buy Regulus Stock please use our How to Invest in Regulus Therapeutics guide.

Latest Regulus Therapeutics' Capital Stock Growth Pattern

Below is the plot of the Capital Stock of Regulus Therapeutics over the last few years. It is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. Regulus Therapeutics' Capital Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Regulus Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Capital Stock

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Capital Stock

Timeline

Regulus Capital Stock Regression Statistics

	Arithmetic Mean	26,450
	Geometric Mean	16,144
	Coefficient Of Variation	143.24
	Mean Deviation	22,280
	Median	9,000
	Standard Deviation	37,886
	Sample Variance	1.4B
	Range	142K
	R-Value	0.44
	Mean Square Error	1.2B
	R-Squared	0.19
	Significance	0.10
	Slope	3,729
	Total Sum of Squares	20.1B

Regulus Capital Stock History

	2024	23.8 K
	2022	22 K
	2021	151 K
	2020	69 K
	2019	25 K

Other Fundumenentals of Regulus Therapeutics

Issuance Of Capital Stock

Regulus Therapeutics Capital Stock component correlations

	Total Assets	Total Stockholder Equity	Accounts Payable	Long Term Debt	Short Term Investments	Total Liab	Intangible Assets	Property Plant Equipment	Current Deferred Revenue	Net Debt	Retained Earnings	Total Current Assets	Short Term Debt	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Common Stock	Net Receivables	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.9	0.36	-0.02	0.95	0.1	0.71	0.23	0.07	-0.55	0.55	0.98	0.22	0.9	0.72	-0.36	-0.48	0.21	0.35	0.55	0.64	0.41	-0.22
Total Stockholder Equity	0.9		0.23	-0.2	0.78	-0.33	0.4	0.09	-0.24	-0.68	0.21	0.9	0.19	0.76	0.44	-0.01	-0.7	0.24	0.48	0.21	0.43	0.36	-0.02
Accounts Payable	0.36	0.23		0.06	0.41	0.28	0.45	0.87	-0.25	-0.07	0.12	0.33	0.34	0.16	0.3	0.01	-0.18	0.29	0.15	0.44	0.32	0.02	-0.32
Long Term Debt	-0.02	-0.2	0.06		0.04	0.41	0.34	0.24	0.46	-0.1	0.41	-0.05	-0.51	-0.04	0.41	-0.54	0.59	-0.18	-0.31	0.3	0.25	0.11	-0.18
Short Term Investments	0.95	0.78	0.41	0.04		0.29	0.84	0.28	0.22	-0.49	0.69	0.94	0.23	0.91	0.8	-0.49	-0.37	0.07	0.28	0.71	0.64	0.28	-0.43
Total Liab	0.1	-0.33	0.28	0.41	0.29		0.68	0.3	0.72	0.34	0.74	0.09	0.07	0.2	0.57	-0.74	0.6	-0.05	-0.3	0.77	0.45	0.05	-0.43
Intangible Assets	0.71	0.4	0.45	0.34	0.84	0.68		0.4	0.59	-0.26	0.92	0.7	0.14	0.71	0.88	-0.79	0.11	0.0	0.09	0.95	0.65	0.15	-0.55
Property Plant Equipment	0.23	0.09	0.87	0.24	0.28	0.3	0.4		-0.19	-0.05	0.08	0.17	0.18	0.01	0.26	-0.07	-0.07	0.16	0.08	0.37	0.16	-0.1	-0.33
Current Deferred Revenue	0.07	-0.24	-0.25	0.46	0.22	0.72	0.59	-0.19		0.19	0.83	0.07	-0.17	0.25	0.53	-0.88	0.69	-0.19	-0.3	0.63	0.35	0.05	-0.3
Net Debt	-0.55	-0.68	-0.07	-0.1	-0.49	0.34	-0.26	-0.05	0.19		-0.16	-0.57	0.38	-0.52	-0.35	0.07	0.52	-0.18	-0.65	-0.09	-0.34	-0.34	-0.11
Retained Earnings	0.55	0.21	0.12	0.41	0.69	0.74	0.92	0.08	0.83	-0.16		0.54	-0.04	0.66	0.84	-0.93	0.33	-0.06	-0.03	0.9	0.66	0.22	-0.45
Total Current Assets	0.98	0.9	0.33	-0.05	0.94	0.09	0.7	0.17	0.07	-0.57	0.54		0.25	0.88	0.7	-0.31	-0.47	0.24	0.38	0.55	0.64	0.4	-0.17
Short Term Debt	0.22	0.19	0.34	-0.51	0.23	0.07	0.14	0.18	-0.17	0.38	-0.04	0.25		0.01	-0.14	0.18	-0.3	0.0	-0.25	0.28	-0.14	-0.37	-0.24
Net Tangible Assets	0.9	0.76	0.16	-0.04	0.91	0.2	0.71	0.01	0.25	-0.52	0.66	0.88	0.01		0.81	-0.48	-0.39	0.04	0.39	0.54	0.64	0.41	-0.31
Long Term Debt Total	0.72	0.44	0.3	0.41	0.8	0.57	0.88	0.26	0.53	-0.35	0.84	0.7	-0.14	0.81		-0.71	0.06	-0.07	0.25	0.76	0.65	0.28	-0.43
Capital Surpluse	-0.36	-0.01	0.01	-0.54	-0.49	-0.74	-0.79	-0.07	-0.88	0.07	-0.93	-0.31	0.18	-0.48	-0.71		-0.49	0.16	0.15	-0.79	-0.56	-0.19	0.45
Deferred Long Term Liab	-0.48	-0.7	-0.18	0.59	-0.37	0.6	0.11	-0.07	0.69	0.52	0.33	-0.47	-0.3	-0.39	0.06	-0.49		-0.07	-0.46	0.23	0.13	0.04	-0.04
Common Stock	0.21	0.24	0.29	-0.18	0.07	-0.05	0.0	0.16	-0.19	-0.18	-0.06	0.24	0.0	0.04	-0.07	0.16	-0.07		0.21	-0.04	0.55	0.7	0.7
Net Receivables	0.35	0.48	0.15	-0.31	0.28	-0.3	0.09	0.08	-0.3	-0.65	-0.03	0.38	-0.25	0.39	0.25	0.15	-0.46	0.21		-0.02	0.25	0.27	0.12
Short Long Term Debt	0.55	0.21	0.44	0.3	0.71	0.77	0.95	0.37	0.63	-0.09	0.9	0.55	0.28	0.54	0.76	-0.79	0.23	-0.04	-0.02		0.58	0.03	-0.56
Net Invested Capital	0.64	0.43	0.32	0.25	0.64	0.45	0.65	0.16	0.35	-0.34	0.66	0.64	-0.14	0.64	0.65	-0.56	0.13	0.55	0.25	0.58		0.83	0.06
Net Working Capital	0.41	0.36	0.02	0.11	0.28	0.05	0.15	-0.1	0.05	-0.34	0.22	0.4	-0.37	0.41	0.28	-0.19	0.04	0.7	0.27	0.03	0.83		0.49
Capital Stock	-0.22	-0.02	-0.32	-0.18	-0.43	-0.43	-0.55	-0.33	-0.3	-0.11	-0.45	-0.17	-0.24	-0.31	-0.43	0.45	-0.04	0.7	0.12	-0.56	0.06	0.49

Click cells to compare fundamentals

About Regulus Therapeutics Financial Statements

Regulus Therapeutics shareholders use historical fundamental indicators, such as Capital Stock, to determine how well the company is positioned to perform in the future. Although Regulus Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Regulus Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Regulus Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Capital Stock	25 K	23.8 K
Issuance Of Capital Stock	15.2 M	18 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Regulus Stock Analysis

When running Regulus Therapeutics' price analysis, check to measure Regulus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regulus Therapeutics is operating at the current time. Most of Regulus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Regulus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regulus Therapeutics' price. Additionally, you may evaluate how the addition of Regulus Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Regulus Capital Stock from 2010 to 2024

Latest Regulus Therapeutics' Capital Stock Growth Pattern

Regulus Capital Stock Regression Statistics

Regulus Capital Stock History

Other Fundumenentals of Regulus Therapeutics

Regulus Therapeutics Capital Stock component correlations

About Regulus Therapeutics Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Regulus Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY